TheraVida and SK Chemicals have signed a licensing deal for the development and commercialisation of THVD-201 and THVD-202, for overactive bladder (OAB) and urge urinary incontinence (UUI), in South Korea.

SK Chemicals is responsible for manufacturing, clinical development, regulatory approval and commercialisation costs of THVD-201 and follow-on product THVD-202 in the territory.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TheraVida is eligible for milestone payments and net sales-based royalties from the products.

SK Chemicals Life Science Business chief executive officer In-Serk Lee said an international Phase II clinical trial had confirmed the highly differentiated clinical profile of THVD-201 relative to tolterodine.

"THVD-201 has the potential to provide a new and unique treatment option for patients in South Korea," Lee said.

"SK Chemicals is responsible for manufacturing, clinical development, regulatory approval and commercialisation costs of THVD-201 and follow-on product THVD-202 in the territory."

"Our collaboration with TheraVida and access to these new products complements our Mvix products and the commitment by SK Chemicals to building our urology franchise, and developing products that improve the quality of life, such as Ginexin, Trast, Mvix and others."

The proprietary twice-daily (BID) formulation of tolterodine and pilocarpine THVD-201 is designed to treat OAB and UUI with reduced dry mouth side effects usually coupled with existing therapies.

THVD-201 has completed Phase I and Phase II development in trials, while the proprietary once-daily (QD) formulation of tolterodine and pilocarpine, THVD-202, is completing pre-clinical development.

TheraVida chief executive officer Dr Roger Flugel said THVD-201 and THVD-202 are potent candidates to offer significant improvement in dry mouth side effects and efficacy compared to existing standard-of-care therapies for OAB and UUI.

"We believe these products can ultimately increase the overall tolerability, compliance, and satisfaction for patients suffering from these conditions," Flugel said.